US stock · Healthcare sector · Diagnostics & Research
Company Logo

Agilent Technologies, Inc.

ANYSE

121.55

USD
-1.19
(-0.97%)
Market Closed
28.55P/E
21Forward P/E
1.42P/E to S&P500
35.984BMarket CAP
0.67%Div Yield
Upcoming Earnings
21 Nov-25 Nov
Shares Short
9/15/22
3.03M
Short % of Float
1.03%
Short % of Shares Outs.
1.02%
% Held by Insiders
0.24%
% Held by Institutions
93.78%
Beta
1.07
PEG Ratio
2.00
52w. high/low
165.68/112.52
Avg. Daily Volume
1.42M
Return %
Stock
S&P 500
1 year
(23.27)
(16.20)
3 years
59.98
22.35
5 years
91.78
44.82
Scale: |
High
Low
28.91
21.65
27.18
10.56
22.73
8.60
30.10
19.08
39.58
20.51
33.10
25.26
41.44
28.75
43.79
35.62
43.59
33.12
48.63
34.15
70.93
45.74
75.11
60.42
85.68
62.00
120.24
61.13
179.57
112.47
159.44
112.52
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
11.54
13.76
15.91
12.95
15.69
19.06
19.71
19.89
20.96
12.13
12.89
13.89
15.31
16.44
17.28
20.79
22.18
Earnings per share
7.67
1.62
1.91
(0.09)
1.97
2.92
3.31
2.12
1.51
1.20
1.42
2.12
0.98
3.41
2.33
3.98
4.42
FCF per share
1.04
2.07
1.66
0.81
1.72
3.09
2.97
2.81
1.52
1.18
2.01
2.21
2.83
2.75
2.60
4.26
3.40
Dividends per share
- -
- -
- -
- -
- -
- -
0.30
0.46
0.53
0.40
0.46
0.53
0.60
0.66
0.72
0.78
0.82
CAPEX per share
0.43
0.39
0.42
0.37
0.35
0.54
0.56
0.57
0.62
0.29
0.43
0.55
0.55
0.50
0.39
0.62
0.94
Book Value per sh.
8.46
8.21
7.05
7.24
9.30
12.41
14.89
15.50
15.91
12.51
13.02
15.00
14.23
15.12
15.77
17.73
17.28
Comm.Shares outs.
431
394
363
346
347
347
348
341
333
333
326
322
321
314
309
304
300
Avg. annual P/E ratio
3.2
15.8
11.3
(173.3)
11.7
10.3
8.6
15.7
26.8
32.8
30.4
27.9
68.4
21.9
39.6
36.2
28.5
P/E to S&P500
0.2
0.9
0.5
(2.4)
0.6
0.6
0.6
0.9
1.5
1.6
1.4
1.2
2.7
0.9
1.0
1.2
1.4
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
1.0%
1.4%
1.3%
1.0%
1.1%
0.9%
0.9%
0.9%
0.8%
0.5%
0.6%
Revenue (m)
4,973
5,420
5,774
4,481
5,444
6,615
6,858
6,782
6,981
4,038
4,202
4,472
4,914
5,163
5,339
6,319
6,659
Operating margin
9.3%
10.8%
13.8%
1.0%
10.4%
16.2%
16.3%
14.0%
11.9%
12.9%
14.6%
18.8%
18.9%
18.2%
15.8%
21.3%
23.1%
Depreciation (m)
170
191
201
162
202
253
301
372
384
253
246
212
210
238
308
321
328
Net profit (m)
3,307
638
693
(31)
684
1,012
1,153
724
504
401
462
684
316
1,071
719
1,210
1,328
Income tax rate
14.5%
4.8%
15.0%
542.9%
1.2%
1.9%
(10.5)%
15.7%
22.0%
8.8%
15.1%
14.8%
66.6%
(16.5)%
14.6%
11.0%
11.9%
Net profit margin
66.5%
11.8%
12.0%
(0.7)%
12.6%
15.3%
16.8%
10.7%
7.2%
9.9%
11.0%
15.3%
6.4%
20.7%
13.5%
19.1%
19.9%
Working capital (m)
2,420
2,008
1,883
2,838
3,086
3,732
2,736
3,381
3,798
2,710
2,690
2,906
2,677
1,109
1,948
2,091
1,788
Long-term debt (m)
1,500
2,087
2,125
2,904
2,190
1,932
2,112
2,699
2,762
1,655
1,912
1,801
1,799
1,791
2,284
2,729
2,732
Equity (m)
3,648
3,234
2,559
2,506
3,228
4,308
5,182
5,286
5,298
4,167
4,243
4,831
4,567
4,748
4,873
5,389
5,091
ROIC
49.9%
10.8%
11.3%
(6.5)%
11.8%
15.2%
14.6%
9.0%
6.5%
7.1%
7.6%
10.5%
4.6%
15.7%
9.6%
14.2%
16.2%
Return on capital
46.2%
8.9%
11.0%
1.2%
8.1%
12.4%
10.9%
9.0%
7.0%
6.8%
7.9%
10.5%
12.0%
10.5%
9.6%
13.5%
15.1%
Return on equity
90.7%
19.7%
27.1%
(1.2)%
21.2%
23.5%
22.3%
13.7%
9.5%
9.6%
10.9%
14.2%
6.9%
22.6%
14.8%
22.5%
26.1%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
91.0%
78.5%
65.1%
66.8%
67.5%
75.1%
39.6%
80.8%
69.1%
80.5%
81.4%
Div.&Repurch./FCF
821.4%
192.5%
131.2%
- -
18.8%
18.0%
17.0%
110.3%
74.3%
101.8%
89.3%
51.1%
67.4%
107.4%
78.7%
79.0%
135.7%
Capital Structure
1 Sep · 2022 | Q3
All numbers in millions
Total liabilities
$ 5,393
Total assets
$ 10,484
Long-term debt
$ 2,732
Cash and equiv.
$ 1,071
Goodwill
$ 3,948
Retained earnings
$ 139
Common stock
298
Enterprise Value
$ 37,645
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
1,382
1,599
1,575
Receivables
930
1,038
1,172
Inventory
679
720
830
Other
198
117
324
Current assets
3,189
3,415
3,799
Acc. Payable
354
354
446
Debt due
616
75
- -
Other
1,110
1,038
1,262
Current liabilities
2,080
1,467
1,708
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
18.36%
9.18%
0.76%
Cash flow
61.60%
19.25%
8.39%
Earnings
68.29%
55.14%
21.75%
Dividends
6.31%
8.57%
10.98%
Book value
10.59%
2.93%
0.92%
Insider Trading
Type
Shares
Date
Mcdonnell Padraig
Sale
2,103
09/28/22
Thaysen Jacob
Sale
5,839
09/09/22
Mcdonnell Padraig
Sale
2,506
09/08/22
Mcmahon Robert W.
InKind
2,303
08/03/22
Mcdonnell Padraig
Sale
1,000
06/30/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
1,357
1,238
1,261
1,483
5,339
2021
1,548
1,525
1,586
1,660
6,319
2022
1,674
1,607
1,718
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.64
0.33
0.64
0.72
2.33
2021
0.95
0.71
0.87
1.45
3.98
2022
0.94
0.92
1.10
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.18
0.18
0.18
0.18
0.72
2021
0.19
0.19
0.19
0.19
0.78
2022
0.21
0.21
0.21
- -
- -
Company Description
Sector:
Healthcare
Industry:
Diagnostics & Research
CEO:
Mr. Michael McMullen
Full-time employees:
17,700
City:
Santa Clara
Address:
5301 Stevens Creek Blvd
IPO:
Nov 18, 1999
Website:
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Recent News
· 24 Nov, 2020 · The Wall Street Journal